 |
|
|
| |
Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from Part C of the Phase 2 FLIGHT-FXR study
|
| |
| |
AASLD 2020 Nov 11-16
Kathryn Jean Lucas,1 Patricia Lopez,2 Eric Lawitz,3 Aasim Sheikh,4 Diego Aizenberg,5 Stanley Hsia,6 George Boon Bee Goh,7 John Vierling,8 Juan Frias,6 Judith White,9 Hirokazu Takahashi,10 Donald Lazas,11 Masato Yoneda,12 Salvador Augustin,13 Won Kim,14 Juergen Loeffler,2 Felicity Schaefer,15 Marilyn Cines,15 Natasha A Sahr,15 Sophie Lamle,2 Miljen Martic,2 Clifford Brass,15 and Arun J Sanyal16
1Diabetes and Endocrinology Consultants, Morehead City, NC, USA; 2Novartis Pharma AG, Basel, Switzerland; 3Texas Liver Institute, University of Texas Health, San Antonio, TX, USA; 4Gastrointestinal Specialists of Georgia, Marietta, GA, USA; 5Centro Medico Viamonte, Buenos Aires, Argentina; 6National Research Institute, Los Angeles, CA, USA; 7Singapore General Hospital, Singapore; 8Advanced Liver Therapies, Baylor College of Medicine, Houston, TX, USA; 9Accelerated Enrollment Solutions, Orlando, FL, USA; 10Liver center, Saga University, Saga, Japan; 11Digestive Health Research/ObjectiveGI, Nashville, TN, USA; 12Department of Gastroenterology and Hepatology, Yokohama City University Hospital, Yokohama, Japan; 13Hospital Vall d'Hebron, Barcelona, Cataluna, Spain; 14Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea; 15Novartis Pharmaceutical Corporation, East Hanover, USA; 16Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA
|
| |
|
|
|
|
|
